FindTrial
Sign In

Valsartan 80 mg

DRUG8 trials

Sponsors

Novartis Pharmaceuticals, Trinity Hypertension & Metabolic Research Institute, LanZhou University, The University of Hong Kong, Mostafa Bahaa

Conditions

Blood PressureDiabetic NephropathiesEssential HypertensionExercise PhysiologyHeart FailureHypertensionHypertension ComplicatedHypertrophy, Left Ventricular

Phase 2

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
CompletedNCT00425373
Novartis PharmaceuticalsEssential Hypertension
Start: 2006-11-30End: 2008-03-31Updated: 2011-04-29
Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease
CompletedNCT05638880
Mostafa BahaaDiabetic Nephropathies
Start: 2022-12-20End: 2025-12-20Updated: 2026-03-31

Phase 3

Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
CompletedNCT00413413
Novartis PharmaceuticalsHypertension
Start: 2007-01-31End: 2007-11-30Updated: 2011-04-28
Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension
CompletedNCT00699192
Novartis PharmaceuticalsHypertension
Start: 2008-05-31End: 2009-05-31Updated: 2011-06-06

Phase 4

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
CompletedNCT03180593
Trinity Hypertension & Metabolic Research InstituteBlood Pressure, Hypertension Complicated, Hypertrophy, Left Ventricular
Start: 2017-02-07End: 2018-01-25Updated: 2018-04-11
Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II
NCT05269615
The University of Hong KongExercise Physiology
Start: 2023-03-20End: 2024-09-30Target: 80Updated: 2024-05-09
Sacubitril/Valsartan Versus Valsartan in Heart Failure
CompletedNCT05881720
Damanhour UniversityHeart Failure
Start: 2022-01-01End: 2023-06-19Updated: 2023-06-27

Unknown Phase

Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women
NCT03432468
LanZhou UniversityHypertension
Start: 2018-04-01End: 2019-08-01Target: 102Updated: 2018-03-13

Related Papers

Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial.
2025-09-10